Dermatology

EULAR points to consider in the match from PSO to PSA. 5 overarching principles and 10 points to consider. The presence of synovitis in PSO could be used as an outcome for prevention trials, Zabotti A et al, Abst#OP0062 #EULAR2023 @RheumNow https://t.co/tbnuhBCjTU

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 04, 2023

Can combined US examination of nail-enthesis complex & nailfold videocapillaroscopy differentiate PsA from PSO RA and HC? Brief answer is no, but: -PsA > tortuous capillaries vs. PSO & HC -Abnormalities in PSO to be used as predictor of PsA? TBC... @RheumNow #EULAR23 POS0025 https://t.co/RNbpht8QGh

Aurelie Najm @AurelieRheumo( View Tweet )

Jun 01, 2023

#EULAR2023 #OP0007 What are the recent trends of autoimmune disease (AID)? A database study (22m) in UK showed: - 1 in 10 people had AID in the last 20yrs - socioeconomic, seasonal & regional disparities cd influence pathogenesis - CTD (SLE,pSS,SSc) tended to co-occur @RheumNow https://t.co/3DDPR2K5NC

Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

May 31, 2023

🚨EULAR PtC clinical & imaging features suspicious for progression to PsA Main take home messages ⬇️⬇️ Obesity, Nail Disease, Extensive PsO, Arthralgia, US detected synovio-entheseal involvement/abnormalities in US = risks factors of developing PsA in PsO pts. @Rheumnow #EULAR23

Aurelie Najm @AurelieRheumo( View Tweet )

May 31, 2023

MSK Symptoms from Dupilimab, an IL-4/13 Inhibitor A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab. https://t.co/xGPSA2oRis https://t.co/y7M42DlM7d

Links:

https://bit.ly/45e7QvO

Dr. John Cush @RheumNow( View Tweet )

May 22, 2023

TNF Inhibitors and Acne? A literature review found 47 refractory acne pts Rx w/ TNFi; noting partial improvement (94%) or clearance (40%) & only 6% w/ adverse events. 17 pts had new-onset acne after Rx w/ TNFi for a different inflamm Dx. Odd! https://t.co/duHEIHBMyK https://t.co/br8NQZQE2r

Links:

https://bit.ly/3ocyOmO

Dr. John Cush @RheumNow( View Tweet )

May 21, 2023

Allergic Drug-Induced Arthritis (5.19.2023)

Save

Jack Cush, MD

May 19, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies.

Subanalysis of the tofacitinib ORAL Surveillance study shows the JAK

Read Article

RCT of 122 active plaque Psoriasis pts (38F, 55M) with low vitamin D (~15). Rx w/ either PBO or Vit D (100K IU, followed by 20K IU/wk x 4 mos). Vitamin D supplementation had no effect on psoriasis severity (but pts had mild PSO). https://t.co/JXtEBaop3c https://t.co/ScGtBUIrm0

Links:

https://bit.ly/438DFnT

Dr. John Cush @RheumNow( View Tweet )

May 18, 2023

Brepocitinib in Active Psoriatic Arthritis

Save

Jack Cush, MD

May 17, 2023

Brepocitinib is a novel tyrosine kinase 2/Janus kinase 1 inhibitor and has been studied in patients with moderately-to-severely active psoriatic arthritis (PsA), showing impressive efficacy at both 16 weeks and 52 weeks.

Brepocitinib is an oral, selective Tyk2/JAK1 inhibitor with both

Read Article

JAK inhibitors in Psoriasis and PsA RheumNow Live 2023: Eric Ruderman, MD, Northwestern University, Feinberg School of Medicine https://t.co/eVwQ6ITzD7 https://t.co/GZxVx77aV1

Links:

https://bit.ly/3VWOPd9

Dr. John Cush @RheumNow( View Tweet )

May 14, 2023

Disappointing Secondary Use of Newer Therapies in Psoriatic Arthritis

Save

Jack Cush, MD

May 12, 2023

Analysis of patient data from five Nordic registries shows that the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) was mainly in biologic-experienced patients. The use of newer b/tsDMARD was hampered by limited

Read Article

One in Ten is Bad! (5.12.2023)

Save

Jack Cush, MD

May 12, 2023

This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease!

Read Article

JAK inhibitors in Psoriasis and PsA RheumNow Live 2023: Eric Ruderman, MD, Northwestern University, Feinberg School of Medicine https://t.co/OV4rRR6eCh https://t.co/uY9MnwGveV

Links:

https://bit.ly/3I1yBcS

Dr. John Cush @RheumNow( View Tweet )

May 11, 2023

National Population Insights (4.28.2023)

Save

Jack Cush, MD

Apr 28, 2023

Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.

Read Article

JAMA Dermatology Patient Education page - Sarcoidosis of the Skin https://t.co/yDbwRUR8DK https://t.co/F8lsoh6s1l

Links:

https://bit.ly/3ArI2xT

Dr. John Cush @RheumNow( View Tweet )

Apr 23, 2023

JAMA Dermatology Patient Education page - Sarcoidosis of the Skin https://t.co/aPbTjl3pXv https://t.co/wCbjlUeFkj

Links:

https://bit.ly/3Awaxed

Dr. John Cush @RheumNow( View Tweet )

Apr 20, 2023

Sex-Specific Differences in Psoriatic Arthritis

Save

Jack Cush, MD

Apr 19, 2023

A systematic review of published literature on psoriatic arthritis (PsA), clinical features, disease activity, and patient-reported outcomes (PROs) shows generally higher levels of disease activity in women, compared to men with PsA.

A metanalysis of published reports on adults with

Read Article

Amgen Wins Otezla Patent Case - Brand Protected till 2028

Save

Reuters

Apr 19, 2023

Amgen Inc convinced a U.S. appeals court on Wednesday to uphold patents that bar generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis AG's Sandoz Inc until 2028.

The U.S. Court of Appeals for the Federal Circuit affirmed a New Jersey

Read Article

Atopic Disease Increases Osteoarthritis Risk Analysis of commercial insurance claims suggests that patients with asthma or atopic dermatitis have a significantly increased risk of osteoarthritis (OA). https://t.co/450DnhOfY5 https://t.co/zUfD4jhumY

Links:

https://bit.ly/3zpnhCy

Dr. John Cush @RheumNow( View Tweet )

Apr 04, 2023

RCT shows vitamin D does not improve psoriasis. 122 mild PSO pts (PASI=3.1) w/ mean low vit D levels 14.9 ng/mL; randomized to vit D (20KIU/wk) or placebo. At 4 mos, vit D levels rose to 30 w/ Rx, but no signif improvement in PASI change, MD global or DLQI https… https://t.co/OI5v1y5t0u

Dr. John Cush @RheumNow( View Tweet )

Mar 31, 2023

The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing authorisation of deucravacitinib (Sotyktu) in the treatment of moderate to severe psoriasis based on the POETYK PSO-1 & POETYK PSO-2 RCTs https://t.co/KBIYSJVFqu . https://t.co/nzuHh6v0ua

Links:

https://bit.ly/40thmIM

Dr. John Cush @RheumNow( View Tweet )

Mar 31, 2023

Atopic Disease Increases Osteoarthritis Risk

Save

Jack Cush, MD

Mar 29, 2023

Analysis of commercial insurance claims suggests that patients with asthma or atopic dermatitis have a significantly increased risk of osteoarthritis.

Read Article

Retrospective study of Apremilast survival in 281 #psoriasis pts(22% w/ PsA) showed 1 yr drug survival=54%, less at 2 yrs (41%), 3 yrs (32%), and 4 yrs (30%). Half 1+ adverse events; D/C mostly for lack of efficacy (27%), adverse events (12%) https://t.co/2dm6H6cYNX https://t.co/F2YtzzWMdT

Links:

https://bit.ly/40aGtjn

Dr. John Cush @RheumNow( View Tweet )

Mar 23, 2023

Dr. John Reveille on genetic sharing between AS, PsO, and IBD - multiple overlapping genetic signals @RheumNow #RNL2023 https://t.co/p3gvfTO732

Robert B Chao, MD @doctorRBC( View Tweet )

Mar 19, 2023

NEJM Case: 44 yoF w/ 1wk hx of pustular rash, 1st on face, then legs. Also has ankle pain & odynophagia. PMHx oral ulcers. Exam: Aphthous ulcers & all labs were negative (ANA, ANCA, HIV, RPR, etc). Skin Bx= small-vessel vasculitis. What Dx? https://t.co/gxjXRaRKzq https://t.co/OYmC4om6hi

Links: